<unk>  was originally derived from a mouse monoclonal antibody generated from mice immunized with the 165-residue form of recombinant human vascular endothelial growth factor. It was humanized by retaining the binding region and replacing the rest with a human full light chain and a human truncated IgG1 heavy chain, with some other substitutions. The resulting plasmid was transfected into Chinese hamster ovary cells which are grown in industrial fermentation systems.
Bevacizumab
Necitumumab
Bortezomib
Panitumumab
Sunitinib
Ranibizumab
Ruxolitinib
Ceritinib